Everything below concerns thymosin alpha-1. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-01-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
| Property | Value | Notes |
|---|---|---|
| Amino acid length | 28 residues | Single chain with an acetylated N-terminus |
| Molecular mass | Approximately 3,108 Da | Small shifts occur with counter-ion and water content |
| Isoelectric point | Around 3.5 | Low value follows from the many acidic residues |
| Parent molecule | N-terminal region of prothymosin alpha | Free circulating form in humans is not firmly established |
| Common synonyms | Thymalfasin; T alpha 1 | Older literature also uses the full spelled-out form |
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
== Medical use == Clinical laboratories can use this growth medium to diagnose and further speciate fungal infections, allowing medical professionals to provide appropriate treatment with antifungal medications. Histoplasma and other fungal causes of atypical pneumonia can be grown on this medium. Sabouraud agar used in combination with additional media, such as Inhibitory Mold Agar (IMA), improves identification of fungal clinical isolates.
Since then, biochemistry has advanced, especially since the mid-20th century, with the development of new techniques such as chromatography, X-ray diffraction, NMR spectroscopy, radioisotopic labelling, electron microscopy and molecular dynamics simulations. These techniques allowed for the discovery and detailed analysis of many molecules and metabolic pathways of the cell, such as glycolysis and the Krebs cycle (citric acid cycle). The example of an NMR instrument shows that some of these instruments, such as the HWB-NMR, can be very large in size and can cost anywhere from a few thousand dollars to millions of dollars ($16 million for the one shown here).
=== Endothelial dysfunction and diabetic would healing === ITGA1 has been associated with vascular dysfunction in diabetic would healing, more specifically diabetic foot ulcers. Increased ITGA1 expression has been observed in diabetic wound tissues and AGEs-treated human umbilical vein endothelial cells (HUVECs). While elevated ITGA1 expression contributes to endothelial cell dysfunction by impairing proliferation, migration, and tube formation, while promoting cellular senescence; inhibiting ITGA1 restores endothelial cell function. This suggests ITGA1's contribution to diabetic wound pathology, and may represent a potential therapeutic target for vascular repair.
Blood transfusions are given as needed to correct anemia and hypotension secondary to hypovolemia in cases of severe bleeding. Infusion of platelet concentrates may also be used in emergency situations as platelet concentrates contain vWF. Vonicog alfa is a recombinant von Willebrand factor that was approved for use in the United States in December 2015, and for use in the European Union in August 2018. If baseline factor VIII activity is >40%, rVWF may be administered as a standalone product when immediate response is needed, but if Factor VIII activity is <40% and immediate response is needed, rVWF must be administered in conjunction with FVIII replacement therapy.
Sources: en.wikipedia.org
=== AI-influencers === One application of generative AI technology is the creation of virtual influencers on platforms such as OnlyFans and Instagram. These characters interact with users, mimicking real human communication and providing a fully synthetic yet convincing experience. The emergence of such influencers has raised concerns regarding consent of individuals whose voices or likenesses were used as training data, as well as the fact that AI interactions blur the line between human-created content and AI-generated material.
The military occupation of Czechoslovakia by Nazi Germany began with the German annexation of the Sudetenland in 1938, continued with the creation of the Protectorate of Bohemia and Moravia, and by the end of 1944 extended to all parts of Czechoslovakia. Following the Anschluss of Austria in March 1938 and the Munich Agreement in September of that same year, Adolf Hitler annexed the Sudetenland from Czechoslovakia on 1 October, giving Germany control of the extensive Czechoslovak border fortifications in this area. The incorporation of the Sudetenland into Germany left the rest of Czechoslovakia ("Rest-Tschechei" ) with a largely indefensible northwestern border. Also a Polish-majority borderland region of Trans-Olza which was annexed by Czechoslovakia in 1919, was occupied and annexed by Poland following the two-decade long territorial dispute. Finally the First Vienna Award gave to Hungary the southern territories of Slovakia and Carpathian Ruthenia, mostly inhabited by Hungarians. On 14 March 1939, the Slovak parliament voted unanimously to establish an independent Slovak state and German troops preemptively marched into Ostrava to prevent the Poles from occupying the region. The following day, during a visit to Berlin, the Czechoslovak president Emil Hácha was coerced into signing away his country's independence as Hungary annexed the remainder of Carpathian Ruthenia. On 16 March, Hitler proclaimed the Protectorate of Bohemia and Moravia from Prague Castle, leaving Hácha as the nominal, but almost powerless, State President.
In the context of nutrition, a mineral is a chemical element. Some "minerals" are essential for life, but most are not. Minerals are one of the four groups of essential nutrients; the others are vitamins, essential fatty acids, and essential amino acids. The five major minerals in the human body are calcium, phosphorus, potassium, sodium, and magnesium. The remaining minerals are called "trace elements". The generally accepted trace elements are iron, chlorine, cobalt, copper, zinc, manganese, molybdenum, iodine, selenium, and bromine; there is some evidence that there may be more. The four organogenic elements, namely carbon, hydrogen, oxygen, and nitrogen (CHON), that comprise roughly 96% of the human body by weight, are usually not considered as minerals (nutrient). In fact, in nutrition, the term "mineral" refers more generally to all the other functional and structural elements found in living organisms. Plants obtain minerals from soil. Animals ingest plants, thus moving minerals up the food chain. Larger organisms may also consume soil (geophagia) or use mineral resources such as salt licks to obtain minerals. Finally, although mineral and elements are in many ways synonymous, minerals are only bioavailable to the extent that they can be absorbed. To be absorbed, minerals either must be soluble or readily extractable by the consuming organism. For example, molybdenum is an essential mineral, but metallic molybdenum has no nutritional benefit. Many molybdates are sources of molybdenum.
He went on to graduate school at the California Institute of Technology (Caltech) in Pasadena, California, under the guidance of Roscoe Dickinson and Richard Tolman. His graduate research involved the use of X-ray diffraction to determine the structure of crystals. He published seven papers on the crystal structure of minerals while he was at Caltech. He received his PhD in physical chemistry and mathematical physics, summa cum laude, in 1925.
==== Costa Rica ==== In August 2024, the first Dunkin' location in Costa Rica opened in Heredia.There are currently, eight locations in operation in Costa Rica: six in San José, one in Cartago, and one in Heredia.
Sources: en.wikipedia.org
It is usually described as an immunomodulatory peptide rather than a classic circulating hormone. No endocrine gland is known to release it as a primary secretory product, and its measured presence in blood is not firmly established.
Prothymosin alpha is a much larger acidic protein, roughly 111 to 113 residues long, and the thymosin alpha-1 sequence matches its N-terminal region. The small peptide is therefore best understood as a fragment of that parent protein rather than a separate gene product.
Trials and clinical reports have examined chronic hepatitis B and C, use as a vaccine adjuvant, and supportive treatment in some immunodeficiency and oncology settings. Results vary by indication, and regulatory approval differs between countries.
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.